Literature DB >> 33846627

Gut-inhabiting Clostridia build human GPCR ligands by conjugating neurotransmitters with diet- and human-derived fatty acids.

Fang-Yuan Chang1,2, Piro Siuti3, Stephane Laurent4, Thomas Williams2, Emerson Glassey1, Andreas W Sailer4, David Benjamin Gordon1,2, Horst Hemmerle3, Christopher A Voigt5,6.   

Abstract

Human physiology is regulated by endogenous signalling compounds, including fatty acid amides (FAAs), chemical mimics of which are made by bacteria. The molecules produced by human-associated microbes are difficult to identify because they may only be made in a local niche or they require a substrate sourced from the host, diet or other microbes. We identified a set of uncharacterized gene clusters in metagenomics data from the human gut microbiome. These clusters were discovered to make FAAs by fusing exogenous fatty acids with amines. Using an in vitro assay, we tested their ability to incorporate 25 fatty acids and 53 amines known to be present in the human gut, from which the production of six FAAs was deduced (oleoyl dopamine, oleoyl tyramine, lauroyl tryptamine, oleoyl aminovaleric acid, α-linolenoyl phenylethylamine and caproyl tryptamine). These molecules were screened against panels of human G-protein-coupled receptors to deduce their putative human targets. Lauroyl tryptamine is found to be an antagonist to the immunomodulatory receptor EBI2 against its native oxysterol ligand (0.98 μM half-maximal inhibitory concentration), is produced in culture by Eubacterium rectale and is present in human faecal samples. FAAs produced by Clostridia may serve as a mechanism to modulate their host by mimicking human signalling molecules.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33846627     DOI: 10.1038/s41564-021-00887-y

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  98 in total

1.  The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota.

Authors:  June L Round; S Melanie Lee; Jennifer Li; Gloria Tran; Bana Jabri; Talal A Chatila; Sarkis K Mazmanian
Journal:  Science       Date:  2011-04-21       Impact factor: 47.728

Review 2.  Bile salt biotransformations by human intestinal bacteria.

Authors:  Jason M Ridlon; Dae-Joong Kang; Phillip B Hylemon
Journal:  J Lipid Res       Date:  2005-11-18       Impact factor: 5.922

Review 3.  Natural product discovery from the human microbiome.

Authors:  Matthew R Wilson; Li Zha; Emily P Balskus
Journal:  J Biol Chem       Date:  2017-04-07       Impact factor: 5.157

Review 4.  Gut microbiota-generated metabolites in animal health and disease.

Authors:  Won-Jae Lee; Koji Hase
Journal:  Nat Chem Biol       Date:  2014-06       Impact factor: 15.040

5.  Molecular structure of the toxin domain of heat-stable enterotoxin produced by a pathogenic strain of Escherichia coli. A putative binding site for a binding protein on rat intestinal epithelial cell membranes.

Authors:  H Ozaki; T Sato; H Kubota; Y Hata; Y Katsube; Y Shimonishi
Journal:  J Biol Chem       Date:  1991-03-25       Impact factor: 5.157

6.  Specialized metabolites from the microbiome in health and disease.

Authors:  Gil Sharon; Neha Garg; Justine Debelius; Rob Knight; Pieter C Dorrestein; Sarkis K Mazmanian
Journal:  Cell Metab       Date:  2014-11-04       Impact factor: 27.287

7.  Discovery of Reactive Microbiota-Derived Metabolites that Inhibit Host Proteases.

Authors:  Chun-Jun Guo; Fang-Yuan Chang; Thomas P Wyche; Keriann M Backus; Timothy M Acker; Masanori Funabashi; Mao Taketani; Mohamed S Donia; Stephen Nayfach; Katherine S Pollard; Charles S Craik; Benjamin F Cravatt; Jon Clardy; Christopher A Voigt; Michael A Fischbach
Journal:  Cell       Date:  2017-01-19       Impact factor: 41.582

Review 8.  HUMAN MICROBIOTA. Small molecules from the human microbiota.

Authors:  Mohamed S Donia; Michael A Fischbach
Journal:  Science       Date:  2015-07-23       Impact factor: 47.728

9.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.

Authors:  Zeneng Wang; Elizabeth Klipfell; Brian J Bennett; Robert Koeth; Bruce S Levison; Brandon Dugar; Ariel E Feldstein; Earl B Britt; Xiaoming Fu; Yoon-Mi Chung; Yuping Wu; Phil Schauer; Jonathan D Smith; Hooman Allayee; W H Wilson Tang; Joseph A DiDonato; Aldons J Lusis; Stanley L Hazen
Journal:  Nature       Date:  2011-04-07       Impact factor: 49.962

10.  Production of α-galactosylceramide by a prominent member of the human gut microbiota.

Authors:  Laura C Wieland Brown; Cristina Penaranda; Purna C Kashyap; Brianna B Williams; Jon Clardy; Mitchell Kronenberg; Justin L Sonnenburg; Laurie E Comstock; Jeffrey A Bluestone; Michael A Fischbach
Journal:  PLoS Biol       Date:  2013-07-16       Impact factor: 8.029

View more
  4 in total

Review 1.  (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders.

Authors:  Jyoti Sihag; Vincenzo Di Marzo
Journal:  Lipids Health Dis       Date:  2022-01-14       Impact factor: 3.876

Review 2.  Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint.

Authors:  Aniello Schiano Moriello; Vincenzo Di Marzo; Stefania Petrosino
Journal:  Animals (Basel)       Date:  2022-01-31       Impact factor: 2.752

Review 3.  Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling.

Authors:  Sevag Hamamah; Armin Aghazarian; Anthony Nazaryan; Andras Hajnal; Mihai Covasa
Journal:  Biomedicines       Date:  2022-02-13

Review 4.  Oxysterols in the Immune Response to Bacterial and Viral Infections.

Authors:  Cheng Xiang Foo; Stacey Bartlett; Katharina Ronacher
Journal:  Cells       Date:  2022-01-07       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.